Cancer Research

Positive Phase III Data Unveiled For New GnRH Blocker Degarelix

MILAN, Italy, March 27 /PRNewswire/--- Degarelix Suppressed Testosterone Within Three Days in 96% of Patients Data from a Phase III study presented at the 23rd Annual European Association of Urology Congress demonstrated that the investigational GnRH bloc ...

Article - Anna Ohlden - Mar 27 2008 - 5:32am

Laureate Announces Second Manufacturing Agreement With Cytheris

PRINCETON, New Jersey and PARIS, March 27 /PRNewswire/--- Laureate to Manufacture Cytheris' Lead Product Candidate, INTERLEUKIN-7, currently in clinical trials for treatment of HIV, HCV and cancer ...

Article - Anna Ohlden - Mar 27 2008 - 7:33am

Human Stem Cells Grow In Self-Assembled Mini-Lab

Northwestern University researchers have discovered a new and unexpected mode of self-assembly involving a polymer (hyaluronic acid) and a small molecule (peptide amphiphiles). When brought together, the two instantly assemble into a flexible but strong sa ...

Article - News Staff - Mar 27 2008 - 1:40pm

Study Results Show Investigational Drug, Prasugrel, Cuts Risk Of Stent-Related Clots By More Than Half Versus Clopidogrel

CHICAGO, March 29 /PRNewswire/--- Reductions seen as soon as three days and out to 450 days in patients who received either bare metal or drug-eluting stents The investigational antiplatelet drug prasugrel plus aspirin produced a marked and highly statist ...

Article - Anna Ohlden - Mar 29 2008 - 8:32am

Genmab Announces Year End 2007 Financial Results

COPENHAGEN, Denmark, March 31 /PRNewswire/--- Genmab Reports Financial Results for the 12 Months Ended December 31, 2007. Genmab A/S (OMX: GEN) announced today results for the financial year ended December 31, 2007. Revenues of DKK 530 million (approximat ...

Article - Anna Ohlden - Mar 31 2008 - 4:34pm

Health Experts Recommend Probiotic Drinks For Patients Taking Antibiotics

LONDON, April 1 /PRNewswire/-- An expert report released today recommends that patients taking antibiotics, especially those being treated in hospital, should take a daily probiotic drink with clinically proven effectiveness. The report summarises a meeti ...

Article - Anna Ohlden - Mar 31 2008 - 6:33pm

Dutch Top Institute Allocates 150 Million Euro To R&D Projects Targeting Early Diagnosis And Treatment Of Disease

EINDHOVEN, the Netherlands, April 1 /PRNewswire/-- The Center for Translational Molecular Medicine (CTMM)- a Dutch public-private partnership committed to the research and development of new techniques for the diagnosis and treatment of major diseases- an ...

Article - Anna Ohlden - Apr 1 2008 - 6:33am

Amsterdam Molecular Therapeutics To Appoint George Morstyn To Supervisory Board

AMSTERDAM, The Netherlands, April 2 /PRNewswire/-- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that AMT's Supervisory Board has decided to propose Dr. George Morstyn to be appointed t ...

Article - Anna Ohlden - Apr 2 2008 - 6:32am

Bavarian Nordic Update- 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process

WASHINGTON DC, April 2 /PRNewswire/-- Bavarian Nordic, the Danish-based biopharmaceutical company, recently published its 2007 Annual Report. Below is an extract of the most significant matters in the report as well as events after the balance sheet date. ...

Article - Anna Ohlden - Apr 2 2008 - 7:30am

Researchers Implicate Two SNPs In Lung Cancer

Researchers in a large, multi-institutional study have found one gene variant that is linked to an increased risk of lung cancer. The research team collected DNA from 1,154 smokers who have lung cancer and 1,137 smokers without lung cancer. Each DNA sample ...

Article - News Staff - Apr 2 2008 - 3:38pm